ArticleInternational journal of genomics2025
A Novel Mitochondria-Associated Programmed Cell Death-Related Prognostic Model and Validation of Oncogene INHBB in Colorectal Cancer.
Article in International journal of genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Novel Mitochondria-Associated Programmed Cell Death-Related Prognostic Model and Validation of Oncogene INHBB in Colorectal Cancer.International journal of genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study is to explore mitochondria-associated programmed cell death (mtPCD)-related key biomarkers for patients with colorectal cancer (CRC). Methods: CRC-related datasets were obtained from the GEO and TCGA databases, and mitochondria-related genes (MitoRGs) and PCD-related genes (PCDRGs) were acquired from the MitoCarta database or pertinent literature. After differentially expressed gene (DEG) screening, the DEmtPCD coexpressed genes were identified. Then, consensus clustering analysis was conducted, followed by GSEA and immune infiltration analysis. In addition, a prognostic model was constructed, and then, immune infiltration analysis, GSEA, and drug sensitivity analysis were carried out. The qRT-PCR and western blot were employed to determine the expression of key genes. Finally, a loss-of-function experiment was applied to investigate the influence of INHBB on CRC in vitro. Results: A total of 2118 DEGs were screened, and then, 64 DEmtPCD coexpressed genes were obtained. Subsequently, two clusters, including C1 and C2, were identified, and patients in the C1 group had better survival outcomes. In addition, a prognostic model was constructed based on four key genes, namely, ACSL6, INHBB, GPR15, and SRPX. Also, the area under the curves (AUCs) for overall survival (OS) at 1, 3, and 5 years were 0.667, 0.665, and 0.603 in the TCGA set, separately, and 0.759, 0.766, and 0.662, separately, in the GSE17537 dataset. The total fraction of nine immune cells showed a significant difference between the low- (L) and high (H)-risk groups, such as neutrophils, activated NK cells, and activated dendritic cells. Also, there was a significant difference in TIDE scores between the H- and L-risk groups, and APC was the most significantly mutated gene in both the H- and L-risk groups. IC Conclusion: A prognostic model was constructed based on four key mtPCD-associated genes, namely, ACSL6, INHBB, GPR15, and SRPX. INHBB was upregulated in CRC, and the alleviation of INHBB suppressed the proliferation and migration of CRC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.